首页> 外文期刊>Fundamental & clinical pharmacology. >Adverse drug reactions associated with the use of NSAIDs: A caseoncase analysis of spontaneous reports from the French pharmacovigilance database 2002-2006
【24h】

Adverse drug reactions associated with the use of NSAIDs: A caseoncase analysis of spontaneous reports from the French pharmacovigilance database 2002-2006

机译:与使用NSAID相关的药物不良反应:来自法国药物警戒数据库2002-2006年自发报告的病例/非病例分析

获取原文
获取原文并翻译 | 示例
       

摘要

To evaluate the safety profile of eight oral nonsteroidal anti-inflammatory drugs (NSAIDs) available in France, using data reported through the French pharmacovigilance system. Data (from 2002 to 2006) were analysed for aceclofenac, diclofenac, ketoprofen, meloxicam, naproxen, nimesulide, piroxicam and tenoxicam, focusing on the reported rates of serious adverse drug reactions (ADRs) in the following system organ classes: gastrointestinal, hepatic, cutaneous, renal and cardiovascular. A total of 42389 serious ADR reports were identified, and 38506 were included in a caseoncase analysis. Ketoprofen was associated with the highest cumulative reported rate of serious ADRs (0.78 cases per million defined daily doses), followed by diclofenac (0.58), nimesulide (0.52), naproxen (0.50), piroxicam (0.47), tenoxicam (0.42), meloxicam (0.41) and aceclofenac (0.30). The most frequently reported serious ADRs were cutaneous, followed by gastrointestinal, hepatic, renal and rarely, cardiovascular events. In the caseoncase analysis, ketoprofen, piroxicam and naproxen were associated with the highest risk of serious gastrointestinal ADRs (odds ratios [ORs] of 6.87, 6.54 and 5.07, respectively). Nimesulide and aceclofenac were associated with the highest risk of liver ADRs (adjusted ORs of 4.53 and 3.67, respectively), as was meloxicam for cutaneous ADRs (adjusted OR of 3.15) and tenoxicam for renal ADRs (adjusted OR of 3.17). The most frequent serious ADRs reported with the selected oral NSAIDs are cutaneous, followed by gastrointestinal, hepatic and renal events. The highest risks for serious gastrointestinal, hepatic, cutaneous and renal adverse events were linked, respectively, with ketoprofen, nimesulide, meloxicam and tenoxicam compared with the other NSAIDs. ? 2011 Soci??t?? Fran?aise de Pharmacologie et de Th??rapeutique.
机译:使用通过法国药物警戒系统报告的数据,评估在法国可获得的八种口服非甾体类抗炎药(NSAID)的安全性。分析了2002年至2006年的醋氯芬酸,双氯芬酸,酮洛芬,美洛昔康,萘普生,尼美舒利,吡罗昔康和替诺昔康的数据,重点是以下系统器官类别中报告的严重药物不良反应(ADR)发生率:胃肠道,肝,皮肤,肾脏和心血管疾病。总共确定了42389份严重的ADR报告,其中38506份包含在病例/非病例分析中。酮洛芬与严重ADR的累积报道率最高相关(每百万确定的每日剂量0.78例),其次是双氯芬酸(0.58),尼美舒利(0.52),萘普生(0.50),吡罗昔康(0.47),替诺昔康(0.42),美洛昔康(0.41)和醋氯芬酸(0.30)。报道最严重的严重ADR是皮肤病,其次是胃肠道,肝,肾和很少的心血管事件。在病例/非病例分析中,酮洛芬,吡罗昔康和萘普生与发生严重胃肠道不良反应的风险最高(比值比[OR]分别为6.87、6.54和5.07)。尼美舒利和醋氯芬酸与肝脏ADR的最高风险相关(分别调整后的OR为4.53和3.67),美洛昔康对皮肤ADR的相关风险(调整后的OR为3.15)和替诺昔康对肾脏ADR的相关风险(调整后的OR为3.17)。选定的口服非甾体抗炎药报告的最常见的严重ADR是皮肤病,其次是胃肠道,肝脏和肾脏事件。严重胃肠道,肝,皮肤和肾脏不良事件的最高风险分别与酮洛芬,尼美舒利,美洛昔康和替诺昔康相比,与其他NSAIDs相关。 ? 2011 Soci ?? t ??法国药典和药典。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号